Neothetics Inc. (Nasdaq: NEOT) reported disappointing results from two Phase 3 trials of LIPO-202 to reduce central abdominal bulging due to subcutaneous fat sending the stock price plummeting $5.76 to $1.37.
Neothetics reports disappointing study results
December 15, 2015 at 12:27 PM EST